Recent advances in the molecular diagnostics of gastric cancer

World Journal of Gastroenterology

Volumn 21, Issue 34, 2015, Pages 9838-9852

  Kanda, Mitsuro ^a   Kodera, Yasuhiro ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Biomarker; DNA methylation; Gastric cancer; Long non coding RNA; MicroRNA; Prognosis

Indexed keywords

AMYLOID BETA PRECURSOR PROTEIN BINDING FAMILY A MEMBER 2; BONE MORPHOGENETIC PROTEIN 4; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLON CANCER ASSOCIATED TRANSCRIPT 1; COMPLEMENTARY RNA; DIHYDROPYRIMIDINASE LIKE 3; ERB B2 RECEPTOR TYROSINE KINASE 3; EXTRACELLULAR HEPARAN SULFATE 6 O ENDOSULFATASE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTER A TRYPSIN INHIBITOR 5; LONG UNTRANSLATED RNA; MICRORNA; MICRORNA 129; MICRORNA 199A 3P; MICRORNA 25; MICRORNA 630; MOLECULAR MARKER; PAIRED BOX GENE 5; REPRIMO; SERPIN PEPTIDASE INHIBITOR CLADE A MEMBER 1; TUMOR MARKER; U BOX CONTAINING PROTEIN 1; UNCLASSIFIED DRUG;

B LYMPHOCYTE; BLOOD SAMPLING; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SCREENING; CHEMOSENSITIVITY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DNA METHYLATION; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; MOLECULAR DIAGNOSTICS; MOLECULAR PATHOLOGY; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; TUMOR SUPPRESSOR GENE; BLOOD; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; MOLECULAR DIAGNOSIS; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROGNOSIS; STOMACH NEOPLASMS;

BIOMARKERS, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICRORNAS; MOLECULAR DIAGNOSTIC TECHNIQUES; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RNA, LONG NONCODING; STOMACH NEOPLASMS;

EID: 84941308697     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i34.9838     Document Type: Review

References (152)

1. Liang H, Kim YH. Identifying molecular drivers of gastric cancer through next-generation sequencing. Cancer Lett 2013; 340: 241-246 [PMID: 23178814 DOI: 10. 1016/j. canlet. 2012. 11. 029]
2. GLOBOCAN 2012. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012, Stomach Cancer. Available from: URL: http://globocan. iarc. fr/Pages/ fact-sheets-cancer. aspx
3. Wang F, Sun GP, Zou YF, Hao JQ, Zhong F, Ren WJ. MicroRNAs as promising biomarkers for gastric cancer. Cancer Biomark 2012; 11: 259-267 [PMID: 23248184 DOI: 10. 3233/cbm-2012-00284]
4. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet 2009; 374: 477-490 [PMID: 19625077 DOI: 10. 1016/s0140-6736(09)60617-6]
5. González CA, Agudo A. Carcinogenesis, prevention and early detection of gastric cancer: where we are and where we should go. Int J Cancer 2012; 130: 745-753 [PMID: 21918974 DOI: 10. 1002/ ijc. 26430]
6. Kanda M, Kobayashi D, Tanaka C, Iwata N, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Nomoto S, Murotani K, Fujiwara M, Kodera Y. Adverse prognostic impact of perioperative allogeneic transfusion on patients with stage II/III gastric cancer. Gastric Cancer 2015; Epub ahead of print [PMID: 25563579 DOI: 10. 1007/s10120-014-0456-x]
7. Cho JY. Molecular diagnosis for personalized target therapy in gastric cancer. J Gastric Cancer 2013; 13: 129-135 [PMID: 24156032 DOI: 10. 5230/jgc. 2013. 13. 3. 129]
8. Durães C, Almeida GM, Seruca R, Oliveira C, Carneiro F. Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? Virchows Arch 2014; 464: 367-378 [PMID: 24487788 DOI: 10. 1007/s00428-013-1533-y]
9. Emoto S, Ishigami H, Yamashita H, Yamaguchi H, Kaisaki S, Kitayama J. Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination. Gastric Cancer 2012; 15: 154-161 [PMID: 21892754 DOI: 10. 1007/s10120-011-0091-8]
10. Kanda M, Fujii T, Takami H, Suenaga M, Inokawa Y, Yamada S, Nakayama G, Sugimoto H, Koike M, Nomoto S, Kodera Y. The combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients. Surg Today 2014; 44: 1692-1701 [PMID: 24114022 DOI: 10. 1007/s00595-013-0752-9]
11. Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, Gotoda T, Lin JT, You WC, Ng EK, Sung JJ. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 2008; 9: 279-287 [PMID: 18308253 DOI: 10. 1016/s1470-2045(08)70072-x]
12. Wu HH, Lin WC, Tsai KW. Advances in molecular biomarkers for gastric cancer: miRNAs as emerging novel cancer markers. Expert Rev Mol Med 2014; 16: e1 [PMID: 24456939 DOI: 10. 1017/ erm. 2013. 16]
13. Janjigian YY, Kelsen DP. Genomic dysregulation in gastric tumors. J Surg Oncol 2013; 107: 237-242 [PMID: 23042588 DOI: 10. 1002/jso. 23263]
14. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513: 202-209 [PMID: 25079317 DOI: 10. 1038/nature13480]
15. Liu HS, Xiao HS. MicroRNAs as potential biomarkers for gastric cancer. World J Gastroenterol 2014; 20: 12007-12017 [PMID: 25232237 DOI: 10. 3748/wjg. v20. i34. 12007]
16. Yasui W, Sentani K, Sakamoto N, Anami K, Naito Y, Oue N. Molecular pathology of gastric cancer: research and practice. Pathol Res Pract 2011; 207: 608-612 [PMID: 22005013 DOI: 10. 1016/j. prp. 2011. 09. 006]
17. Lin LL, Huang HC, Juan HF. Discovery of biomarkers for gastric cancer: a proteomics approach. J Proteomics 2012; 75: 3081-3097 [PMID: 22498886 DOI: 10. 1016/j. jprot. 2012. 03. 046]
18. McLean MH, El-Omar EM. Genetics of gastric cancer. Nat Rev Gastroenterol Hepatol 2014; 11: 664-674 [PMID: 25134511 DOI: 10. 1038/nrgastro. 2014. 143]
19. Razzak M. Genetics: new molecular classification of gastric adenocarcinoma proposed by The Cancer Genome Atlas. Nat Rev Clin Oncol 2014; 11: 499 [PMID: 25113841 DOI: 10. 1038/ nrclinonc. 2014. 138]
20. Hur K, Han TS, Jung EJ, Yu J, Lee HJ, Kim WH, Goel A, Yang HK. Up-regulated expression of sulfatases (SULF1 and SULF2) as prognostic and metastasis predictive markers in human gastric cancer. J Pathol 2012; 228: 88-98 [PMID: 22653794 DOI: 10. 1002/path. 4055]
21. Lee J, Goh SH, Song N, Hwang JA, Nam S, Choi IJ, Shin A, Kim IH, Ju MH, Jeong JS, Lee YS. Overexpression of IFITM1 has clinicopathologic effects on gastric cancer and is regulated by an epigenetic mechanism. Am J Pathol 2012; 181: 43-52 [PMID: 22609115 DOI: 10. 1016/j. ajpath. 2012. 03. 027]
22. Meng XY, Zhou CH, Ma J, Jiang C, Ji P. Expression of interleukin-and its clinical significance in gastric cancer patients. Med Oncol 2012; 29: 3024-3028 [PMID: 22744708 DOI: 10. 1007/ s12032-012-0273-1]
23. Yu J, Gao J, Lu Z, Li Y, Shen L. Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine. Med Oncol 2012; 29: 3029-3034 [PMID: 22766748 DOI: 10. 1007/s12032-012-0292-y]
24. Ivanova T, Zouridis H, Wu Y, Cheng LL, Tan IB, Gopalakrishnan V, Ooi CH, Lee J, Qin L, Wu J, Lee M, Rha SY, Huang D, Liem N, Yeoh KG, Yong WP, Teh BT, Tan P. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Gut 2013; 62: 22-33 [PMID: 22535375 DOI: 10. 1136/ gutjnl-2011-301113]
25. Zhou F, Qiu W, Yao R, Xiang J, Sun X, Liu S, Lv J, Yue L. CRM1 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas. Med Oncol 2013; 30: 726 [PMID: 24026662 DOI: 10. 1007/s12032-013-0726-1]
26. Chu D, Zhu S, Li J, Ji G, Wang W, Wu G, Zheng J. CD147 expression in human gastric cancer is associated with tumor recurrence and prognosis. PLoS One 2014; 9: e101027 [PMID: 24979746 DOI: 10. 1371/journal. pone. 0101027]
27. Deng N, Liu JW, Sun LP, Xu Q, Duan ZP, Dong NN, Yuan Y. Expression of XPG protein in the development, progression and prognosis of gastric cancer. PLoS One 2014; 9: e108704 [PMID: 25268735 DOI: 10. 1371/journal. pone. 0108704]
28. Deng X, Liu P, Zhao Y, Wang Q. Expression profiling of CEACAM6 associated with the tumorigenesis and progression in gastric adenocarcinoma. Genet Mol Res 2014; 13: 7686-7697 [PMID: 25299082 DOI: 10. 4238/2014. September. 26. 6]
29. Ema A, Yamashita K, Ushiku H, Kojo K, Minatani N, Kikuchi M, Mieno H, Moriya H, Hosoda K, Katada N, Kikuchi S, Watanabe M. Immunohistochemical analysis of RTKs expression identified HER3 as a prognostic indicator of gastric cancer. Cancer Sci 2014; 105: 1591-1600 [PMID: 25455899 DOI: 10. 1111/cas. 12556]
30. Fang Z, Tian Z, Luo K, Song H, Yi J. Clinical significance of stanniocalcin expression in tissue and serum of gastric cancer patients. Chin J Cancer Res 2014; 26: 602-610 [PMID: 25400427 DOI: 10. 3978/j. issn. 1000-9604. 2014. 10. 08]
31. Hedner C, Gaber A, Korkocic D, Nodin B, Uhlén M, Kuteeva E, Johannesson H, Jirström K, Eberhard J. SATB1 is an independent prognostic factor in radically resected upper gastrointestinal tract adenocarcinoma. Virchows Arch 2014; 465: 649-659 [PMID: 25326863 DOI: 10. 1007/s00428-014-1667-6]
32. Hu CE, Liu YC, Zhang HD, Huang GJ. JMJD2A predicts prognosis and regulates cell growth in human gastric cancer. Biochem Biophys Res Commun 2014; 449: 1-7 [PMID: 24802408 DOI: 10. 1016/j. bbrc. 2014. 04. 126]
33. Kanda M, Nomoto S, Oya H, Shimizu D, Takami H, Hibino S, Hashimoto R, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y. Dihydropyrimidinase-like 3 facilitates malignant behavior of gastric cancer. J Exp Clin Cancer Res 2014; 33: 66 [PMID: 25096402 DOI: 10. 1186/s13046-014-0066-9]
34. Kwon CH, Park HJ, Lee JR, Kim HK, Jeon TY, Jo HJ, Kim DH, Kim GH, Park DY. Serpin peptidase inhibitor clade A member 1 is a biomarker of poor prognosis in gastric cancer. Br J Cancer 2014; 111: 1993-2002 [PMID: 25211665 DOI: 10. 1038/bjc. 2014. 490]
35. Shi H, Ji M, Wu J, Zhou Q, Li X, Li Z, Zheng X, Xu B, Zhao W, Wu C, Jiang J. Serum B7-H4 expression is a significant prognostic indicator for patients with gastric cancer. World J Surg Oncol 2014; 12: 188 [PMID: 24947047 DOI: 10. 1186/1477-7819-12-188]
36. Sun A, Yu G, Dou X, Yan X, Yang W, Lin Q. Nedd4-1 is an exceptional prognostic biomarker for gastric cardia adenocarcinoma and functionally associated with metastasis. Mol Cancer 2014; 13: 248 [PMID: 25395181 DOI: 10. 1186/1476-4598-13-248]
37. Ye XT, Guo AJ, Yin PF, Cao XD, Chang JC. Overexpression of NUAK1 is associated with disease-free survival and overall survival in patients with gastric cancer. Med Oncol 2014; 31: 61 [PMID: 24943992 DOI: 10. 1007/s12032-014-0061-1]
38. Zhang J, Zhang K, Jiang X, Zhang J. S100A6 as a potential serum prognostic biomarker and therapeutic target in gastric cancer. Dig Dis Sci 2014; 59: 2136-2144 [PMID: 24705642 DOI: 10. 1007/ s10620-014-3137-z]
39. Chen S, Tang J, Huang L, Lin J. Expression and prognostic value of Mycl1 in gastric cancer. Biochem Biophys Res Commun 2015; 456: 879-883 [PMID: 25528583 DOI: 10. 1016/j. bbrc. 2014. 12. 060]
40. Chen SZ, Yao HQ, Zhu SZ, Li QY, Guo GH, Yu J. Expression levels of matrix metalloproteinase-9 in human gastric carcinoma. Oncol Lett 2015; 9: 915-919 [PMID: 25621068 DOI: 10. 3892/ ol. 2014. 2768]
41. Guo T, Yu Y, Yip GW, Baeg GH, Thike AA, Lim TK, Tan PH, Matsumoto K, Bay BH. Y-box binding protein 1 is correlated with lymph node metastasis in intestinal-type gastric cancer. Histopathology 2015; 66: 491-499 [PMID: 25270600 DOI: 10. 1111/his. 12570]
42. Ma L, Wang X, Lan F, Yu Y, Ouyang X, Liu W, Xie F, Huang Q. Prognostic value of differential CCND1 expression in patients with resected gastric adenocarcinoma. Med Oncol 2015; 32: 338 [PMID: 25452171 DOI: 10. 1007/s12032-014-0338-4]
43. Xu MD, Dong L, Qi P, Weng WW, Shen XH, Ni SJ, Huang D, Tan C, Sheng WQ, Zhou XY, Du X. Pituitary tumor-transforming gene-1 serves as an independent prognostic biomarker for gastric cancer. Gastric Cancer 2015; Epub ahead of print [PMID: 25627474 DOI: 10. 1007/s10120-015-0459-2]
44. Kanda M, Nomoto S, Oya H, Takami H, Shimizu D, Hibino S, Hashimoto R, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y. The Expression of Melanoma-Associated Antigen D2 Both in Surgically Resected and Serum Samples Serves as Clinically Relevant Biomarker of Gastric Cancer Progression. Ann Surg Oncol 2015; Epub ahead of print [PMID: 25743330 DOI: 10. 1245/ s10434-015-4457-8]
45. Pinto M, Oliveira C, Cirnes L, Carlos Machado J, Ramires M, Nogueira A, Carneiro F, Seruca R. Promoter methylation of TGFbeta receptor I and mutation of TGFbeta receptor II are frequent events in MSI sporadic gastric carcinomas. J Pathol 2003; 200: 32-38 [PMID: 12692838 DOI: 10. 1002/path. 1327]
46. Oya H, Kanda M, Sugimoto H, Shimizu D, Takami H, Hibino S, Hashimoto R, Okamura Y, Yamada S, Fujii T, Nakayama G, Koike M, Nomoto S, Fujiwara M, Kodera Y. Dihydropyrimidinaselike is a putative hepatocellular carcinoma tumor suppressor. J Gastroenterol 2015; 50: 590-600 [PMID: 25173447 DOI: 10. 1007/ s00535-014-0993-4]
47. Rosslenbroich V, Dai L, Baader SL, Noegel AA, Gieselmann V, Kappler J. Collapsin response mediator protein-4 regulates F-actin bundling. Exp Cell Res 2005; 310: 434-444 [PMID: 16181627 DOI: 10. 1016/j. yexcr. 2005. 08. 005]
48. Kawahara T, Hotta N, Ozawa Y, Kato S, Kano K, Yokoyama Y, Nagino M, Takahashi T, Yanagisawa K. Quantitative proteomic profiling identifies DPYSL3 as pancreatic ductal adenocarcinomaassociated molecule that regulates cell adhesion and migration by stabilization of focal adhesion complex. PLoS One 2013; 8: e79654 [PMID: 24339867 DOI: 10. 1371/journal. pone. 0079654]
49. Gao X, Pang J, Li LY, Liu WP, Di JM, Sun QP, Fang YQ, Liu XP, Pu XY, He D, Li MT, Su ZL, Li BY. Expression profiling identifies new function of collapsin response mediator protein 4 as a metastasis-suppressor in prostate cancer. Oncogene 2010; 29: 4555-4566 [PMID: 20543870 DOI: 10. 1038/onc. 2010. 213]
50. Begnami MD, Fukuda E, Fregnani JH, Nonogaki S, Montagnini AL, da Costa WL, Soares FA. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 2011; 29: 3030-3036 [PMID: 21709195 DOI: 10. 1200/ jco. 2010. 33. 6313]
51. Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pandiella A, Amir E. HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst 2013; 105: 266-273 [PMID: 23221996 DOI: 10. 1093/jnci/djs501]
52. Allgayer H, Babic R, Grützner KU, Beyer BC, Tarabichi A, Schildberg FW, Heiss MM. Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns. Clin Exp Metastasis 1998; 16: 62-73 [PMID: 9502078]
53. Dhoot GK, Gustafsson MK, Ai X, Sun W, Standiford DM, Emerson CP. Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase. Science 2001; 293: 1663-1666 [PMID: 11533491 DOI: 10. 1126/science. 293. 5535. 1663]
54. Morimoto-Tomita M, Uchimura K, Werb Z, Hemmerich S, Rosen SD. Cloning and characterization of two extracellular heparindegrading endosulfatases in mice and humans. J Biol Chem 2002; 277: 49175-49185 [PMID: 12368295 DOI: 10. 1074/jbc. M205131200]
55. Jang BG, Kim WH. Molecular pathology of gastric carcinoma. Pathobiology 2011; 78: 302-310 [PMID: 22104201 DOI: 10. 1159/000321703]
56. Wang S, Wu X, Zhang J, Chen Y, Xu J, Xia X, He S, Qiang F, Li A, Shu Y, Røe OD, Li G, Zhou JW. CHIP functions as a novel suppressor of tumour angiogenesis with prognostic significance in human gastric cancer. Gut 2013; 62: 496-508 [PMID: 22535373 DOI: 10. 1136/gutjnl-2011-301522]
57. Cheng Y, Jia C, Li G, Li H. Expression of eukaryotic initiation factor 3f is associated with prognosis in gastric carcinomas. Oncol Res Treat 2014; 37: 198-202 [PMID: 24732644 DOI: 10. 1159/000360779]
58. Huang JY, Xu YY, Sun Z, Wang ZN, Zhu Z, Song YX, Luo Y, Zhang X, Xu HM. Low junctional adhesion molecule A expression correlates with poor prognosis in gastric cancer. J Surg Res 2014; 192: 494-502 [PMID: 25033702 DOI: 10. 1016/j. jss. 2014. 06. 025]
59. Kanda M, Oya H, Nomoto S, Takami H, Shimizu D, Hashimoto R, Sueoka S, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y. Diversity of clinical implication of B-cell translocation gene 1 expression by histopathologic and anatomic subtypes of gastric cancer. Dig Dis Sci 2015; 60: 1256-1264 [PMID: 25487193 DOI: 10. 1007/ s10620-014-3477-8]
60. Mai C, Zhao JJ, Tang XF, Wang W, Pan K, Pan QZ, Zhang XF, Jiang SS, Zhao BW, Li YF, Xia JC, Zhou ZW. Decreased ITIH5 expression is associated with poor prognosis in primary gastric cancer. Med Oncol 2014; 31: 53 [PMID: 24913813 DOI: 10. 1007/ s12032-014-0053-1]
61. Sun T, Du W, Xiong H, Yu Y, Weng Y, Ren L, Zhao H, Wang Y, Chen Y, Xu J, Xiang Y, Qin W, Cao W, Zou W, Chen H, Hong J, Fang JY. TMEFF2 deregulation contributes to gastric carcinogenesis and indicates poor survival outcome. Clin Cancer Res 2014; 20: 4689-4704 [PMID: 24987055 DOI: 10. 1158/1078-0432. ccr-14-0315]
62. Tang C, Gao X, Liu H, Jiang T, Zhai X. Decreased expression of SEMA3A is associated with poor prognosis in gastric carcinoma. Int J Clin Exp Pathol 2014; 7: 4782-4794 [PMID: 25197349]
63. Rouault JP, Rimokh R, Tessa C, Paranhos G, Ffrench M, Duret L, Garoccio M, Germain D, Samarut J, Magaud JP. BTG1, a member of a new family of antiproliferative genes. EMBO J 1992; 11: 1663-1670 [PMID: 1373383]
64. Nahta R, Yuan LX, Fiterman DJ, Zhang L, Symmans WF, Ueno NT, Esteva FJ. B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells. Mol Cancer Ther 2006; 5: 1593-1601 [PMID: 16818519 DOI: 10. 1158/1535-7163. mct-06-0133]
65. Kanda M, Sugimoto H, Nomoto S, Oya H, Hibino S, Shimizu D, Takami H, Hashimoto R, Okamura Y, Yamada S, Fujii T, Nakayama G, Koike M, Fujiwara M, Kodera Y. Bcell translocation gene 1 serves as a novel prognostic indicator of hepatocellular carcinoma. Int J Oncol 2015; 46: 641-648 [PMID: 25405901 DOI: 10. 3892/ijo. 2014. 2762]
66. Sheng SH, Zhao CM, Sun GG. BTG1 expression correlates with the pathogenesis and progression of breast carcinomas. Tumour Biol 2014; 35: 3317-3326 [PMID: 24272202 DOI: 10. 1007/ s13277-013-1437-0]
67. Sun GG, Lu YF, Cheng YJ, Hu WN. The expression of BTG1 is downregulated in NSCLC and possibly associated with tumor metastasis. Tumour Biol 2014; 35: 2949-2957 [PMID: 24264312 DOI: 10. 1007/s13277-013-1379-6]
68. Kanda M, Matthaei H, Wu J, Hong SM, Yu J, Borges M, Hruban RH, Maitra A, Kinzler K, Vogelstein B, Goggins M. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 2012; 142: 730-733. e9 [PMID: 22226782 DOI: 10. 1053/j. gastro. 2011. 12. 042]
69. Kanda M, Knight S, Topazian M, Syngal S, Farrell J, Lee J, Kamel I, Lennon AM, Borges M, Young A, Fujiwara S, Seike J, Eshleman J, Hruban RH, Canto MI, Goggins M. Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut 2013; 62: 1024-1033 [PMID: 22859495 DOI: 10. 1136/ gutjnl-2012-302823]
70. Himmelfarb M, Klopocki E, Grube S, Staub E, Klaman I, Hinzmann B, Kristiansen G, Rosenthal A, Dürst M, Dahl E. ITIH5, a novel member of the inter-alpha-trypsin inhibitor heavy chain family is downregulated in breast cancer. Cancer Lett 2004; 204: 69-77 [PMID: 14744536]
71. Veeck J, Chorovicer M, Naami A, Breuer E, Zafrakas M, Bektas N, Dürst M, Kristiansen G, Wild PJ, Hartmann A, Knuechel R, Dahl E. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation. Oncogene 2008; 27: 865-876 [PMID: 17653090 DOI: 10. 1038/sj. onc. 1210669]
72. Esser C, Alberti S, Höhfeld J. Cooperation of molecular chaperones with the ubiquitin/proteasome system. Biochim Biophys Acta 2004; 1695: 171-188 [PMID: 15571814 DOI: 10. 1016/ j. bbamcr. 2004. 09. 020]
73. Connell P, Ballinger CA, Jiang J, Wu Y, Thompson LJ, Höhfeld J, Patterson C. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol 2001; 3: 93-96 [PMID: 11146632 DOI: 10. 1038/35050618]
74. Muller P, Hrstka R, Coomber D, Lane DP, Vojtesek B. Chaperonedependent stabilization and degradation of p53 mutants. Oncogene 2008; 27: 3371-3383 [PMID: 18223694 DOI: 10. 1038/ sj. onc. 1211010]
75. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16: 6-21 [PMID: 11782440 DOI: 10. 1101/gad. 947102]
76. Bird A. Perceptions of epigenetics. Nature 2007; 447: 396-398 [PMID: 17522671 DOI: 10. 1038/nature05913]
77. Calcagno DQ, Gigek CO, Chen ES, Burbano RR, Smith Mde A. DNA and histone methylation in gastric carcinogenesis. World J Gastroenterol 2013; 19: 1182-1192 [PMID: 23482412 DOI: 10. 3748/wjg. v19. i8. 1182]
78. Terry MB, Delgado-Cruzata L, Vin-Raviv N, Wu HC, Santella RM. DNA methylation in white blood cells: association with risk factors in epidemiologic studies. Epigenetics 2011; 6: 828-837 [PMID: 21636973]
79. Matsusaka K, Funata S, Fukayama M, Kaneda A. DNA methylation in gastric cancer, related to Helicobacter pylori and Epstein-Barr virus. World J Gastroenterol 2014; 20: 3916-3926 [PMID: 24744581 DOI: 10. 3748/wjg. v20. i14. 3916]
80. Kobayashi D, Nomoto S, Kodera Y, Fujiwara M, Koike M, Nakayama G, Ohashi N, Nakao A. Suppressor of cytokine signaling 4 detected as a novel gastric cancer suppressor gene using double combination array analysis. World J Surg 2012; 36: 362-372 [PMID: 22127425 DOI: 10. 1007/s00268-011-1358-2]
81. Li X, Cheung KF, Ma X, Tian L, Zhao J, Go MY, Shen B, Cheng AS, Ying J, Tao Q, Sung JJ, Kung HF, Yu J. Epigenetic inactivation of paired box gene 5, a novel tumor suppressor gene, through direct upregulation of p53 is associated with prognosis in gastric cancer patients. Oncogene 2012; 31: 3419-3430 [PMID: 22105368 DOI: 10. 1038/onc. 2011. 511]
82. Takamaru H, Yamamoto E, Suzuki H, Nojima M, Maruyama R, Yamano HO, Yoshikawa K, Kimura T, Harada T, Ashida M, Suzuki R, Yamamoto H, Kai M, Tokino T, Sugai T, Imai K, Toyota M, Shinomura Y. Aberrant methylation of RASGRF1 is associated with an epigenetic field defect and increased risk of gastric cancer. Cancer Prev Res (Phila) 2012; 5: 1203-1212 [PMID: 22961779 DOI: 10. 1158/1940-6207. capr-12-0056]
83. Balgkouranidou I, Karayiannakis A, Matthaios D, Bolanaki H, Tripsianis G, Tentes AA, Lianidou E, Chatzaki E, Fiska A, Lambropoulou M, Kolios G, Kakolyris S. Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival. Clin Chem Lab Med 2013; 51: 1505-1510 [PMID: 23403728 DOI: 10. 1515/cclm-2012-0320]
84. Guo W, Dong Z, Guo Y, Chen Z, Kuang G, Yang Z. Methylationmediated repression of GADD45A and GADD45G expression in gastric cardia adenocarcinoma. Int J Cancer 2013; 133: 2043-2053 [PMID: 23616123 DOI: 10. 1002/ijc. 28223]
85. Ling ZQ, Lv P, Lu XX, Yu JL, Han J, Ying LS, Zhu X, Zhu WY, Fang XH, Wang S, Wu YC. Circulating Methylated XAF1 DNA Indicates Poor Prognosis for Gastric Cancer. PLoS One 2013; 8: e67195 [PMID: 23826230 DOI: 10. 1371/journal. pone. 0067195]
86. Ooki A, Yamashita K, Yamaguchi K, Mondal A, Nishimiya H, Watanabe M. DNA damage-inducible gene, reprimo functions as a tumor suppressor and is suppressed by promoter methylation in gastric cancer. Mol Cancer Res 2013; 11: 1362-1374 [PMID: 23982217 DOI: 10. 1158/1541-7786. mcr-13-0091]
87. Tanaka T, Nakamura J, Kitajima Y, Kai K, Miyake S, Hiraki M, Ide T, Koga Y, Noshiro H. Loss of trefoil factor 1 is regulated by DNA methylation and is an independent predictive factor for poor survival in advanced gastric cancer. Int J Oncol 2013; 42: 894-902 [PMID: 23291975 DOI: 10. 3892/ijo. 2013. 1759]
88. Feng G, Zhang Y, Yuan H, Bai R, Zheng J, Zhang J, Song M. DNA methylation of trefoil factor 1 (TFF1) is associated with the tumorigenesis of gastric carcinoma. Mol Med Rep 2014; 9: 109-117 [PMID: 24190027 DOI: 10. 3892/mmr. 2013. 1772]
89. Han J, Lv P, Yu JL, Wu YC, Zhu X, Hong LL, Zhu WY, Yu QM, Wang XB, Li P, Ling ZQ. Circulating methylated MINT2 promoter DNA is a potential poor prognostic factor in gastric cancer. Dig Dis Sci 2014; 59: 1160-1168 [PMID: 24385013 DOI: 10. 1007/ s10620-013-3007-0]
90. Han L, Dong Z, Wang C, Guo Y, Shen S, Kuang G, Guo W. Decreased expression and aberrant methylation of RASSF5A correlates with malignant progression of gastric cardia adenocarcinoma. Mol Carcinog 2014; Epub ahead of print [PMID: 25420558 DOI: 10. 1002/mc. 22245]
91. Kanda M, Nomoto S, Oya H, Hashimoto R, Takami H, Shimizu D, Sonohara F, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Murotani K, Fujiwara M, Kodera Y. Decreased expression of prenyl diphosphate synthase subunit 2 correlates with reduced survival of patients with gastric cancer. J Exp Clin Cancer Res 2014; 33: 88 [PMID: 25330808 DOI: 10. 1186/s13046-014-0088-3]
92. Kanda M, Shimizu D, Nomoto S, Hibino S, Oya H, Takami H, Kobayashi D, Yamada S, Inokawa Y, Tanaka C, Fujii T, Sugimoto H, Koike M, Fujiwara M, Kodera Y. Clinical significance of expression and epigenetic profiling of TUSC1 in gastric cancer. J Surg Oncol 2014; 110: 136-144 [PMID: 24700496 DOI: 10. 1002/ jso. 23614]
93. Li DX, Cai HY, Wang X, Feng YL, Cai SW. Promoter methylation of Raf kinase inhibitory protein: A significant prognostic indicator for patients with gastric adenocarcinoma. Exp Ther Med 2014; 8: 844-850 [PMID: 25120612 DOI: 10. 3892/etm. 2014. 1833]
94. Otani K, Dong Y, Li X, Lu J, Zhang N, Xu L, Go MY, Ng EK, Arakawa T, Chan FK, Sung JJ, Yu J. Odd-skipped related 1 is a novel tumour suppressor gene and a potential prognostic biomarker in gastric cancer. J Pathol 2014; 234: 302-315 [PMID: 24931004 DOI: 10. 1002/path. 4391]
95. Zhang H, Song Y, Xia P, Cheng Y, Guo Q, Diao D, Wang W, Wu X, Liu D, Dang C. Detection of aberrant hypermethylated spastic paraplegia-20 as a potential biomarker and prognostic factor in gastric cancer. Med Oncol 2014; 31: 830 [PMID: 24381142 DOI: 10. 1007/s12032-013-0830-2]
96. Kanda M, Shimizu D, Nomoto S, Takami H, Hibino S, Oya H, Hashimoto R, Suenaga M, Inokawa Y, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y. Prognostic impact of expression and methylation status of DENN/MADD domain-containing protein 2D in gastric cancer. Gastric Cancer 2015; 18: 288-296 [PMID: 24695972 DOI: 10. 1007/s10120-014-0372-0]
97. Yang Z, Li DM, Xie Q, Dai DQ. Protein expression and promoter methylation of the candidate biomarker TCF21 in gastric cancer. J Cancer Res Clin Oncol 2015; 141: 211-220 [PMID: 25156819 DOI: 10. 1007/s00432-014-1809-x]
98. Hao Y, Chai KH, McLoughlin DM, Chan HY, Lau KF. Promoter characterization and genomic organization of the human X11 gene APBA2. Neuroreport 2012; 23: 146-151 [PMID: 22222501 DOI: 10. 1097/WNR. 0b013e32834f1934]
99. Kanda M, Nomoto S, Oya H, Takami H, Hibino S, Hishida M, Suenaga M, Yamada S, Inokawa Y, Nishikawa Y, Asai M, Fujii T, Sugimoto H, Kodera Y. Downregulation of DENND2D by promoter hypermethylation is associated with early recurrence of hepatocellular carcinoma. Int J Oncol 2014; 44: 44-52 [PMID: 24189587 DOI: 10. 3892/ijo. 2013. 2165]
100. Marat AL, Dokainish H, McPherson PS. DENN domain proteins: regulators of Rab GTPases. J Biol Chem 2011; 286: 13791-13800 [PMID: 21330364 DOI: 10. 1074/jbc. R110. 217067]
101. Liu W, Li X, Chu ES, Go MY, Xu L, Zhao G, Li L, Dai N, Si J, Tao Q, Sung JJ, Yu J. Paired box gene 5 is a novel tumor suppressor in hepatocellular carcinoma through interaction with p53 signaling pathway. Hepatology 2011; 53: 843-853 [PMID: 21319196 DOI: 10. 1002/hep. 24124]
102. Nutt SL, Urbánek P, Rolink A, Busslinger M. Essential functions of Pax5 (BSAP) in pro-B cell development: difference between fetal and adult B lymphopoiesis and reduced V-to-DJ recombination at the IgH locus. Genes Dev 1997; 11: 476-491 [PMID: 9042861]
103. Ohki R, Nemoto J, Murasawa H, Oda E, Inazawa J, Tanaka N, Taniguchi T. Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase. J Biol Chem 2000; 275: 22627-22630 [PMID: 10930422 DOI: 10. 1074/jbc. C000235200]
104. Zhang Z, Li J, Lantry LE, Wang Y, Wiseman RW, Lubet RA, You M. p53 transgenic mice are highly susceptible to 1, 2-dimethylhydrazine-induced uterine sarcomas. Cancer Res 2002; 62: 3024-3029 [PMID: 12036908]
105. Pogribny IP, Rusyn I. Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett 2014; 342: 223-230 [PMID: 22306342 DOI: 10. 1016/ j. canlet. 2012. 01. 038]
106. Toiyama Y, Okugawa Y, Goel A. DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer. Biochem Biophys Res Commun 2014; 455: 43-57 [PMID: 25128828 DOI: 10. 1016/j. bbrc. 2014. 08. 001]
107. Wang J, Song YX, Wang ZN. Non-coding RNAs in gastric cancer. Gene 2015; 560: 1-8 [PMID: 25659765 DOI: 10. 1016/ j. gene. 2015. 02. 004]
108. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008; 48: 2047-2063 [PMID: 19003900 DOI: 10. 1002/hep. 22580]
109. Li BS, Zhao YL, Guo G, Li W, Zhu ED, Luo X, Mao XH, Zou QM, Yu PW, Zuo QF, Li N, Tang B, Liu KY, Xiao B. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One 2012; 7: e41629 [PMID: 22860003 DOI: 10. 1371/journal. pone. 0041629]
110. Tsai KW, Liao YL, Wu CW, Hu LY, Li SC, Chan WC, Ho MR, Lai CH, Kao HW, Fang WL, Huang KH, Lin WC. Aberrant expression of miR-196a in gastric cancers and correlation with recurrence. Genes Chromosomes Cancer 2012; 51: 394-401 [PMID: 22420029]
111. Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V, Iglesias-Díaz P, Lorenzo-Patiño MJ, Haz M, Santamarina I, Blanco M, Fernández-T ajes J, Quindós M, Carral A, Figueroa A, Antón-Aparicio LM, Calvo L. Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J Transl Med 2012; 10: [PMID: 22954417 DOI: 10. 1186/1479-5876-10-186]
112. Wang M, Gu H, Wang S, Qian H, Zhu W, Zhang L, Zhao C, Tao Y, Xu W. Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer. Mol Med Rep 2012; 5: 1514-1520 [PMID: 22406928 DOI: 10. 3892/mmr. 2012. 828]
113. Cui MH, Hou XL, Lei XY, Mu FH, Yang GB, Yue L, Fu Y, Yi GX. Upregulation of microRNA 181c expression in gastric cancer tissues and plasma. Asian Pac J Cancer Prev 2013; 14: 3063-3066 [PMID: 23803080]
114. Deng M, Tang HL, Lu XH, Liu MY, Lu XM, Gu YX, Liu JF, He ZM. miR-26a suppresses tumor growth and metastasis by targeting FGF9 in gastric cancer. PLoS One 2013; 8: e72662 [PMID: 24015269 DOI: 10. 1371/journal. pone. 0072662]
115. Li C, Li JF, Cai Q, Qiu QQ, Yan M, Liu BY, Zhu ZG. miRNA-199a-3p in plasma as a potential diagnostic biomarker for gastric cancer. Ann Surg Oncol 2013; 20 Suppl 3: S397-S405 [PMID: 22956063 DOI: 10. 1245/s10434-012-2600-3]
116. Song J, Bai Z, Zhang J, Meng H, Cai J, Deng W, Bi J, Ma X, Zhang Z. Serum microRNA-21 levels are related to tumor size in gastric cancer patients but cannot predict prognosis. Oncol Lett 2013; 6: 1733-1737 [PMID: 24260069 DOI: 10. 3892/ ol. 2013. 1626]
117. Wang W, Li F, Zhang Y, Tu Y, Yang Q, Gao X. Reduced expression of miR-22 in gastric cancer is related to clinicopathologic characteristics or patient prognosis. Diagn Pathol 2013; 8: 102 [PMID: 23786758 DOI: 10. 1186/1746-1596-8-102]
118. Yu X, Luo L, Wu Y, Yu X, Liu Y, Yu X, Zhao X, Zhang X, Cui L, Ye G, Le Y, Guo J. Gastric juice miR-129 as a potential biomarker for screening gastric cancer. Med Oncol 2013; 30: 365 [PMID: 23307240 DOI: 10. 1007/s12032-012-0365-y]
119. Chen B, Huang T, Jiang J, Lv L, Li H, Xia S. miR-141 suppresses proliferation and motility of gastric cancer cells by targeting HDGF. Mol Cell Biochem 2014; 388: 211-218 [PMID: 24276755 DOI: 10. 1007/s11010-013-1912-3]
120. Chu D, Zhao Z, Li Y, Li J, Zheng J, Wang W, Zhao Q, Ji G. Increased microRNA-630 expression in gastric cancer is associated with poor overall survival. PLoS One 2014; 9: e90526 [PMID: 24621930 DOI: 10. 1371/journal. pone. 0090526]
121. Fu Z, Qian F, Yang X, Jiang H, Chen Y, Liu S. Circulating miR-222 in plasma and its potential diagnostic and prognostic value in gastric cancer. Med Oncol 2014; 31: 164 [PMID: 25129310 DOI: 10. 1007/s12032-014-0164-8]
122. Gu W, Gao T, Shen J, Sun Y, Zheng X, Wang J, Ma J, Hu XY, Li J, Hu MJ. MicroRNA-183 inhibits apoptosis and promotes proliferation and invasion of gastric cancer cells by targeting PDCD4. Int J Clin Exp Med 2014; 7: 2519-2529 [PMID: 25356105]
123. Huang D, Wang H, Liu R, Li H, Ge S, Bai M, Deng T, Yao G, Ba Y. miRNA27a is a biomarker for predicting chemosensitivity and prognosis in metastatic or recurrent gastric cancer. J Cell Biochem 2014; 115: 549-556 [PMID: 24122958 DOI: 10. 1002/jcb. 24689]
124. Li BS, Zuo QF, Zhao YL, Xiao B, Zhuang Y, Mao XH, Wu C, Yang SM, Zeng H, Zou QM, Guo G. MicroRNA-25 promotes gastric cancer migration, invasion and proliferation by directly targeting transducer of ERBB2, 1 and correlates with poor survival. Oncogene 2015; 34: 2556-2565 [PMID: 25043310 DOI: 10. 1038/ onc. 2014. 214]
125. Liu X, Yu H, Cai H, Wang Y. The expression and clinical significance of miR-132 in gastric cancer patients. Diagn Pathol 2014; 9: 57 [PMID: 24621117 DOI: 10. 1186/1746-1596-9-57]
126. Peng WZ, Ma R, Wang F, Yu J, Liu ZB. Role of miR-191/425 cluster in tumorigenesis and diagnosis of gastric cancer. Int J Mol Sci 2014; 15: 4031-4048 [PMID: 24603541 DOI: 10. 3390/ ijms15034031]
127. Sun J, Song Y, Wang Z, Wang G, Gao P, Chen X, Gao Z, Xu H. Clinical significance of promoter region hypermethylation of microRNA-148a in gastrointestinal cancers. Onco Targets Ther 2014; 7: 853-863 [PMID: 24920927 DOI: 10. 2147/ott. s60888]
128. Suzuki R, Yamamoto E, Nojima M, Maruyama R, Yamano HO, Yoshikawa K, Kimura T, Harada T, Ashida M, Niinuma T, Sato A, Nosho K, Yamamoto H, Kai M, Sugai T, Imai K, Suzuki H, Shinomura Y. Aberrant methylation of microRNA-34b/c is a predictive marker of metachronous gastric cancer risk. J Gastroenterol 2014; 49: 1135-1144 [PMID: 23942619 DOI: 10. 1007/s00535-013-0861-7]
129. Tan Z, Jiang H, Wu Y, Xie L, Dai W, Tang H, Tang S. miR-185 is an independent prognosis factor and suppresses tumor metastasis in gastric cancer. Mol Cell Biochem 2014; 386: 223-231 [PMID: 24352663 DOI: 10. 1007/s11010-013-1860-y]
130. Wang H, Wang L, Wu Z, Sun R, Jin H, Ma J, Liu L, Ling R, Yi J, Wang L, Bian J, Chen J, Li N, Yuan S, Yun J. Three dysregulated microRNAs in serum as novel biomarkers for gastric cancer screening. Med Oncol 2014; 31: 298 [PMID: 25367852 DOI: 10. 1007/s12032-014-0298-8]
131. Wang YW, Shi DB, Chen X, Gao C, Gao P. Clinicopathological significance of microRNA-214 in gastric cancer and its effect on cell biological behaviour. PLoS One 2014; 9: e91307 [PMID: 24614175 DOI: 10. 1371/journal. pone. 0091307]
132. Zeng Q, Jin C, Chen W, Xia F, Wang Q, Fan F, Du J, Guo Y, Lin C, Yang K, Li J, Peng X, Li X, Cao K. Downregulation of serum miR-17 and miR-106b levels in gastric cancer and benign gastric diseases. Chin J Cancer Res 2014; 26: 711-716 [PMID: 25561770 DOI: 10. 3978/j. issn. 1000-9604. 2014. 12. 03]
133. Zhang R, Wang W, Li F, Zhang H, Liu J. MicroRNA-106b~25 expressions in tumor tissues and plasma of patients with gastric cancers. Med Oncol 2014; 31: 243 [PMID: 25218271 DOI: 10. 1007/s12032-014-0243-x]
134. Zhu ED, Li N, Li BS, Li W, Zhang WJ, Mao XH, Guo G, Zou QM, Xiao B. miR-30b, down-regulated in gastric cancer, promotes apoptosis and suppresses tumor growth by targeting plasminogen activator inhibitor-1. PLoS One 2014; 9: e106049 [PMID: 25170877 DOI: 10. 1371/journal. pone. 0106049]
135. Han TS, Hur K, Xu G, Choi B, Okugawa Y, Toiyama Y, Oshima H, Oshima M, Lee HJ, Kim VN, Chang AN, Goel A, Yang HK. MicroRNA-29c mediates initiation of gastric carcinogenesis by directly targeting ITGB1. Gut 2015; 64: 203-214 [PMID: 24870620 DOI: 10. 1136/gutjnl-2013-306640]
136. Xu YJ, Fan Y. MiR-215/192 participates in gastric cancer progression. Clin Transl Oncol 2015; 17: 34-40 [PMID: 24981590 DOI: 10. 1007/s12094-014-1194-6]
137. Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, Ambros VR, Israel MA. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 2007; 67: 2456-2468 [PMID: 17363563 DOI: 10. 1158/0008-5472. can-06-2698]
138. Wu J, Qian J, Li C, Kwok L, Cheng F, Liu P, Perdomo C, Kotton D, Vaziri C, Anderlind C, Spira A, Cardoso WV, Lü J. miR-129 regulates cell proliferation by downregulating Cdk6 expression. Cell Cycle 2010; 9: 1809-1818 [PMID: 20404570]
139. Farhana L, Dawson MI, Murshed F, Das JK, Rishi AK, Fontana JA. Upregulation of miR-150 and miR-630 induces apoptosis in pancreatic cancer cells by targeting IGF-1R. PLoS One 2013; 8: e61015 [PMID: 23675407 DOI: 10. 1371/journal. pone. 0061015]
140. Zhang Y, Ma M, Liu W, Ding W, Yu H. Enhanced expression of long noncoding RNA CARLo-5 is associated with the development of gastric cancer. Int J Clin Exp Pathol 2014; 7: 8471-8479 [PMID: 25674211]
141. Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet 2014; 15: 7-21 [PMID: 24296535 DOI: 10. 1038/nrg3606]
142. Dong L, Qi P, Xu MD, Ni SJ, Huang D, Xu QH, Weng WW, Tan C, Sheng WQ, Zhou XY, Du X. Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls. Int J Cancer 2015; Epub ahead of print [PMID: 25694351 DOI: 10. 1002/ijc. 29484]
143. Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder R, Trauner M, Zatloukal K. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 2007; 132: 330-342 [PMID: 17241883 DOI: 10. 1053/j. gastro. 2006. 08. 026]
144. Emadi-Andani E, Nikpour P, Emadi-Baygi M, Bidmeshkipour A. Association of HOTAIR expression in gastric carcinoma with invasion and distant metastasis. Adv Biomed Res 2014; 3: 135 [PMID: 24949306 DOI: 10. 4103/2277-9175. 133278]
145. Hu Y, Wang J, Qian J, Kong X, Tang J, Wang Y, Chen H, Hong J, Zou W, Chen Y, Xu J, Fang JY. Long noncoding RNA GAPLINC regulates CD44-dependent cell invasiveness and associates with poor prognosis of gastric cancer. Cancer Res 2014; 74: 6890-6902 [PMID: 25277524 DOI: 10. 1158/0008-5472. can-14-0686]
146. Chen WM, Huang MD, Kong R, Xu TP, Zhang EB, Xia R, Sun M, De W, Shu YQ. Antisense Long Noncoding RNA HIF1A-AS2 Is Upregulated in Gastric Cancer and Associated with Poor Prognosis. Dig Dis Sci 2015; 60: 1655-1662 [PMID: 25686741 DOI: 10. 1007/ s10620-015-3524-0]
147. Hu Y, Pan J, Wang Y, Li L, Huang Y. Long noncoding RNA linc-UBC1 is negative prognostic factor and exhibits tumor prooncogenic activity in gastric cancer. Int J Clin Exp Pathol 2015; 8: 594-600 [PMID: 25755750]
148. Kim T, Cui R, Jeon YJ, Lee JH, Lee JH, Sim H, Park JK, Fadda P, Tili E, Nakanishi H, Huh MI, Kim SH, Cho JH, Sung BH, Peng Y, Lee TJ, Luo Z, Sun HL, Wei H, Alder H, Oh JS, Shim KS, Ko SB, Croce CM. Long-range interaction and correlation between MYC enhancer and oncogenic long noncoding RNA CARLo-5. Proc Natl Acad Sci USA 2014; 111: 4173-4178 [PMID: 24594601 DOI: 10. 1073/pnas. 1400350111]
149. Thrash-Bingham CA, Tartof KD. aHIF: a natural antisense transcript overexpressed in human renal cancer and during hypoxia. J Natl Cancer Inst 1999; 91: 143-151 [PMID: 9923855]
150. Rossignol F, Vaché C, Clottes E. Natural antisense transcripts of hypoxia-inducible factor 1alpha are detected in different normal and tumour human tissues. Gene 2002; 299: 135-140 [PMID: 12459261]
151. Bertozzi D, Iurlaro R, Sordet O, Marinello J, Zaffaroni N, Capranico G. Characterization of novel antisense HIF-1 transcripts in human cancers. Cell Cycle 2011; 10: 3189-3197 [PMID: 21897117]
152. Resende C, Thiel A, Machado JC, Ristimäki A. Gastric cancer: basic aspects. Helicobacter 2011; 16 Suppl 1: 38-44 [PMID: 21896084 DOI: 10. 1111/j. 1523-5378. 2011. 00879. x]